Navigation Links
Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
Date:3/21/2011

ces and comprehensive inhalation drug development to advance aerosol therapies where drug and device can be optimized together.  Online at www.paripharma.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to the results of clinical trials, the development of our products, or the business strategies, plans and objectives of management, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements.  The risks and uncertainties include, without limitation, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, we may experience delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2010.  Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:
Brian Ritchie - FD
212-850-5683
brian.ritchie@fd.com

Media Contact:
Irma Gomez-Dib - FD
212-850-5761
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
2. Insmed to Host Second Quarter 2009 Conference Call
3. Insmed Announces Addition to the Russell 3000(R) Index
4. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
5. Insmed CEO Resigns Due to Health Concerns
6. Insmed Announces First Quarter 2009 Financial Results
7. Insmed Regains NASDAQ Compliance
8. Insmed to Host First Quarter 2009 Conference Call
9. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
10. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
11. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical market is ... the molecular diagnostics industry. BCC Research reveals in its new report that the market ... costs, and a growing need for better diagnostics as part of a molecular diagnostics ...
(Date:7/1/2015)... and BANGALORE, India , July 1, ... company that uses next generation sequencing technology to empower ... A. Storrer as chief executive officer. In his ... be responsible for all strategy, business expansion and worldwide ... has served as Strand,s chairman and CEO since its ...
Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3
... at the Swedish medical university Karolinska Institutet shows that ... LDL cholesterol and thereby cause an inflammation that leads ... cell receptors, the researchers have managed to inhibit the ... online in the distinguished periodical Journal of Experimental ...
... Concludes restatement of prior financial results , , ... call at 4:30 EDT today , , ... May 6 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY ) (the "Company") today ... Company also announced today that it filed its Annual Report on Form 10-K for the ...
... The Netherlands , May 6, 2010 ... CRXL ; Swiss,Exchange: CRX) today announced the award from ... its paediatric vaccine Quinvaxem(R) to the developing,world. Paediatric vaccination ... Development Goals set by the United Nations, in,particular the ...
Cached Biology Technology:New atherosclerosis vaccine gives promising results 2Oncothyreon reports full year and fourth quarter 2009 financial results 2Oncothyreon reports full year and fourth quarter 2009 financial results 3Oncothyreon reports full year and fourth quarter 2009 financial results 4Oncothyreon reports full year and fourth quarter 2009 financial results 5Oncothyreon reports full year and fourth quarter 2009 financial results 6Oncothyreon reports full year and fourth quarter 2009 financial results 7Oncothyreon reports full year and fourth quarter 2009 financial results 8Oncothyreon reports full year and fourth quarter 2009 financial results 9Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World 2Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World 3Crucell Announces New Award of $110 Million for Paediatric Vaccine Quinvaxem(R) by UNICEF to Support Vaccination Programs in the Developing World 4
(Date:6/30/2015)... YORK , June 30, 2015 To bolster ... security provider HYPR Corp. announced today the addition of two ... will serve as board advisor and David Raviv ... the team underscore HYPR Corp.,s commitment to providing the most ... Dimitri Sirota co-founded Layer 7 Technologies, a provider ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... Chip" developed at the University of Colorado at Boulder ... strains from patient samples within hours may help world ... last month on the new technology by the Centers ... CU-Boulder Flu Chip can determine the genetic make-up of ...
... old, in fact, which comes as a surprise to a ... the world's largest tropical region. , Using radiocarbon dating methods, ... up to half of all trees greater than 10 centimeters ... the trees, Trumbore said, are as much as 750 to ...
... (NCI) and the National Human Genome Research Institute ... Health (NIH), today launched a comprehensive effort to ... cancer through the application of genome analysis technologies, ... The Cancer Genome Atlas (TCGA), will begin with ...
Cached Biology News:New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 2New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 3New U. of Colorado at Boulder flu chip may help combat future epidemics, pandemics 4Amazon trees much older than assumed, raising questions on global climate impact of region 2NIH launches comprehensive effort to explore cancer genomics 2NIH launches comprehensive effort to explore cancer genomics 3NIH launches comprehensive effort to explore cancer genomics 4
... White crystalline solid. PACKAGED UNDER ... Contaminants: DNases, proteases, RNases: none ... nm): ≤0.500; (100 mM, 1 cm, 280 ... Soluble in H 2 O. RTECS ...
... Genome ChIP-on-chip Microarray is specifically designed ... cerevisiae) DNA binding proteins by pairing ... microarrays. This set delivers robust hybridization ... true binding events and fewer false ...
... Salmonella genomes has allowed the development of ... pairs. The S. enterica Typhimurium (strain LT2) ... bp; 4,440 ORFs) and a plasmid, pSLT ... Sigma-Genosys have been designed to amplify all ...
... productivity and allows you to achieve a higher ... beyond traditional paper-based weighing processes into a powerful ... Control of ... PR, SR, PG-S, PG, SG, AT, MT, UMT, ...
Biology Products: